ELOXX PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $60.65 per share for the 12-month period ending 2017-06-30, per its 10-K filed 2017-10-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2017-10-13
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2016-09-30 was $25.00, a 21.88% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2015-09-30 was $32.00.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2014-09-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2013-09-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2017 was $60.65, a 450.36% increase from fiscal 2016.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2016 was $11.02, a 96.19% decline from fiscal 2015.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2015 was $289.09, a 25.88% increase from fiscal 2014.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2014 was $229.65, a 13.69% increase from fiscal 2013.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2017-06-30 | $60.65 10-K · filed 2017-10-13 | ||||
| 2017-03-31 | $62.93 10-Q · filed 2017-05-22 | ||||
| 2016-12-31 | $64.66 10-Q · filed 2017-02-10 | ||||
| 2016-09-30 | $25.00 10-Q · filed 2016-11-14 | ||||
| 2016-06-30 | $11.02 10-K · filed 2017-10-13 | ||||
| 2016-03-31 | $10.88 10-Q · filed 2016-05-12 | ||||
| 2015-12-31 | $10.72 10-Q · filed 2016-02-16 | ||||
| 2015-09-30 | $32.00 10-Q · filed 2015-11-16 | ||||
| 2015-06-30 | $289.09 10-K · filed 2017-10-13 | ||||
| 2015-03-31 | $301.70 10-Q · filed 2015-05-14 | ||||
| 2014-12-31 | $301.70 10-Q · filed 2015-02-17 | ||||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-14 | ||||
| 2014-06-30 | $229.65 10-K · filed 2016-10-13 | ||||
| 2014-03-31 | $239.74 10-Q · filed 2014-05-09 | ||||
| 2013-12-31 | $255.88 10-Q · filed 2014-02-14 | ||||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-14 | ||||
| 2013-06-30 | $202.00 10-K · filed 2015-10-09 | $2.02 10-K · filed 2013-09-11 | |||
| 2013-03-31 | $1.95 10-Q · filed 2013-05-15 | ||||
| 2012-12-31 | $1.65 10-Q · filed 2013-02-14 | ||||
| 2012-06-30 | $232.00 10-K · filed 2014-09-29 | $2.32 10-K · filed 2013-09-11 | |||
| 2011-06-30 | $1.14 10-K · filed 2013-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |